Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06669754 is registered in ClinicalTrials.gov with Pharvaris Netherlands B.V. as lead sponsor.

NCT NCT06669754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06669754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Lead sponsor
Pharvaris Netherlands B.V.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 1, 2024
Completion date
August 31, 2026
Enrollment
81 (estimated)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)